Biocaptiva Ltd, an Edinburgh, Scotland-based company developing a cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management, raised £2.1m in additional seed funding.
The round was led by existing investor Archangels, which was joined by Scottish Enterprise and Cancer Research Horizon, and new investor Old College Capital.
The money will be used for the company’s first in-human trial with BioCaptis. This is expected to produce its first data before 2022 ends.
Biocaptiva’s CEO, Jeremy Wheeler is leading the development of the BioCaptis medical device. This will transform liquid biopsy testing in cancer management by improving the early detection and monitoring of disease, and enhancing the clinical trial data for patients with cancer.
The BioCaptis can capture up to 100x more cell-free DNA (cfDNA), than a venous blood drawing. This allows for high quality, quantity cfDNA for testing. It also addresses the main challenge of liquid biopsy in cancer management. This could allow for the testing of more types of cancer and earlier stages of disease in a wider variety of patients.